文献速递瓣膜外科

低风险医保人群中外科与经导管主动脉瓣置换的比较

Surgical versus transcatheter aortic valve replacement in low-risk Medicare beneficiaries.
PubMed 文献 · J Thorac Cardiovasc Surg · 2024-04-28

基于美国医保索赔数据库2018—2020年数据,纳入低风险人群行孤立SAVR(n=8144)或TAVR(n=7605)。TAVR围术期卒中与住院死亡率更低,但3年卒中、瓣膜再干预及全因死亡风险更高。

要点

  • TAVR围术期卒中(OR 0.62)和住院死亡率(OR 0.16)低于SAVR。
  • TAVR远期卒中(HR 1.65)、瓣膜再干预(HR 1.88)和全因死亡(HR 1.54)风险高于SAVR。
  • 低风险医保人群中选择SAVR者3年风险校正结局更优。

核心结论

  • 在75岁以下行孤立主动脉瓣置换的低风险医保人群中,SAVR与更高的围术期并发症和死亡率相关,但3年风险校正后卒中、瓣膜再干预和生存结局优于TAVR。

研究设计与样本

  • 基于美国医疗保险和医疗补助服务中心索赔数据库的回顾性队列研究,纳入2018—2020年行孤立SAVR(n=33210)或TAVR(n=77885)的受益人,并筛选出低风险队列(SAVR n=8144,TAVR n=7605)。
  • 采用逆概率加权和多层回归模型进行双重稳健风险校正,并行竞争风险时间事件分析。

主要发现

  • TAVR与较低的围术期卒中(OR 0.62,P<.001)和住院死亡率(OR 0.16,P<.001)相关。
  • 风险校正纵向分析显示TAVR与较高的远期卒中(HR 1.65,P<.001)、瓣膜再干预再入院(HR 1.88,P<.001)和全因死亡(HR 1.54,P<.001)风险相关。

临床怎么用

  • 作者认为,在75岁以下行孤立主动脉瓣置换的低风险医保人群中,SAVR与更高的围术期并发症和死亡率相关,但3年风险校正后卒中、瓣膜再干预和生存结局优于TAVR。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Recent approval of transcatheter aortic valve replacement (TAVR) in patients at low surgical risk has resulted in a rapid real-world expansion of TAVR in patients not otherwise examined in recent low-risk trials. We sought to evaluate the outcomes of surgical aortic valve replacement (SAVR) versus TAVR in low-risk Medicare beneficiaries. METHODS: Using the US Centers for Medicare and Medicaid Services claims database, we evaluated all beneficiaries undergoing isolated SAVR (n = 33,210) or TAVR (n = 77,885) (2018-2020). International Classification of Diseases 10th revision codes were used to define variables and frailty was defined by the validated Kim index. Doubly robust risk adjustment was performed with inverse probability weighting and multilevel regression models, as well as competing-risk time to event analysis. A low-risk cohort was identified to simulate recent low-risk trials. RESULTS: A total of 15,749 low-risk patients (8144 SAVR and 7605 TAVR) were identified. Comparison was performed with doubly robust risk adjustment accounting for all factors. TAVR was associated with lower perioperative stroke (odds ratio, 0.62; P < .001) and hospital mortality (odds ratio, 0.16; P < .001) compared with SAVR. However, risk-adjusted longitudinal analysis demonstrated TAVR was associated with higher late risk of stroke (hazard ratio, 1.65; P < .001), readmission for valve reintervention (hazard ratio, 1.88; P < .001), and all-cause mortality (hazard ratio, 1.54; P < .001) compared with SAVR. CONCLUSIONS: Among low-risk Medicare beneficiaries younger than age 75 years undergoing isolated AVR, SAVR was associated with higher index morbidity and mortality but improved 3-year risk-adjusted stroke, valve reintervention, and survival compared with TAVR.

来源:J Thorac Cardiovasc Surg,查看原文。版权归原作者所有。

引用

  1. Mehaffey JH, Kawsara M, Jagadeesan V, et al. Surgical versus transcatheter aortic valve replacement in low-risk Medicare beneficiaries. J Thorac Cardiovasc Surg. 2024. PMID: 38688449. doi:10.1016/j.jtcvs.2024.04.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。